Company news
Ars Pharmaceuticals, Inc. (NASDAQ:SPRY) news
Every Ars Pharmaceuticals, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
ARS Pharmaceuticals Outlines Strategic Priorities, including a Focused Commercial Strategy, and Reports Second Quarter 2026 Financial Res...
August 13, 2026
ARS Pharmaceuticals Announces Conference Call and Webcast on August 13 Outlining its Updated Strategic Priorities and Reporting Second Qu...
August 3, 2026
ARS Pharmaceuticals Announces CEO Succession
July 7, 2026
ARS Pharmaceuticals Provides Commercial and Financial Updates
June 24, 2026
Drew Brees Collaborates with ARS Pharmaceuticals to Raise Awareness About Living Life with Severe Allergies
June 4, 2026
ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update
May 15, 2026
ARS Pharmaceuticals Strengthens Leadership Team with Appointment of Industry Veteran Donn Casale as President
May 13, 2026
ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2026 Financial Results
May 7, 2026
neffy® (epinephrine nasal spray) Approved in Canada as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphyla...
April 15, 2026
ARS Pharmaceuticals Receives FDA Approval to Remove Age Requirement From neffy 1 mg Label
March 30, 2026
ARS Pharmaceuticals Receives FDA Approval to Remove Age Requirement From neffy® 1 mg (epinephrine nasal spray) Label
March 27, 2026
ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy® (epinephrine nasal spray) Commercia...
March 9, 2026
ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2025 Financial Results and Participation a...
February 23, 2026
ARS Pharmaceuticals to Showcase Scientific Innovation and Robust Clinical Data on neffy® (epinephrine nasal spray) at 2026 American Acade...
February 10, 2026
EURneffy® 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, includin...
February 2, 2026
ARS Pharmaceuticals, Inc. - California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free Epinephrine at No Cost ...
January 22, 2026
California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free Epinephrine at No Cost for Emergency Use
January 21, 2026
ARS Pharmaceuticals - neffy Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic React...
December 30, 2025
neffy® (epinephrine nasal spray) Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic ...
December 29, 2025
ARS Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference
November 26, 2025
ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy® (epinephrine nasal spray)
November 10, 2025
ARS Pharma Launches Get neffy® on Us for Patients with Severe Allergic Reactions to Improve Access to neffy (epinephrine nasal spray)
November 4, 2025
ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual S...
November 3, 2025
ARS Pharmaceuticals Announces Conference Call and Webcast for its Third Quarter 2025 Financial Results
November 3, 2025
UPDATE -- ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI...
November 3, 2025
ARS Pharmaceuticals Receives Favorable Decision from European Patent Office on Patent Related to neffy® (epinephrine nasal spray)
October 8, 2025
RA Capital Management Funds Expansion of ARS Pharma Commercial Activity, Expands Portfolio of Financing Solutions for Innovative Healthca...
September 30, 2025
ARS Pharmaceuticals Secures Up to $250 Million Loan Facility with RA Capital Management and OMERS Life Sciences to Accelerate U.S. Commer...
September 29, 2025
neffy® (epinephrine nasal spray) Approved in Japan as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
September 19, 2025
ADARx Pharmaceuticals Appoints Industry Veteran, Laura Shawver, Ph.D., as Board Chair
September 17, 2025
80% of Prior Authorizations Automated, 75% Fewer Denials: SPRY Unveils Prior Auth & Eligibility Solution for Rehab Therapy Clinics
September 15, 2025
Real-World Evidence Supports Clinical Effectiveness of neffy® (epinephrine nasal spray) in Patients Experiencing Anaphylaxis
September 8, 2025
ARS Pharmaceuticals to Participate in Upcoming Investor Conferences
August 28, 2025
ARS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Accelerating Growth for neffy® (epinephrine nasal spray)
August 13, 2025
ARS Pharmaceuticals Announces Conference Call and Webcast for its Second Quarter 2025 Financial Results
August 4, 2025
EURneffy® (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anap...
July 18, 2025
ARS Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Progress in U.S. Commercial Launch of neffy® (epinephrine...
May 14, 2025
ARS Pharmaceuticals’ neffy® (epinephrine nasal spray) 1 mg is Now Available in the United States for Type I Allergic Reactions, including...
May 7, 2025
ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2025 Financial Results
May 5, 2025
ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abelló A/S to Expand Reach of neffy® (epi...
May 2, 2025
ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
March 20, 2025
ARS Pharmaceuticals Announces FDA Approval of neffy® 1 mg (epinephrine nasal spray) for Type I Allergic Reactions, Including Anaphylaxis,...
March 5, 2025
ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2024 Financial Results and Participation a...
March 3, 2025
ARS Pharmaceuticals Announces OptumRx, Cigna Healthcare and Navitus Health Systems Add neffy® (Epinephrine Nasal Spray) to National Formu...
February 20, 2025
ARS Pharmaceuticals to Showcase Innovation and Present Data on neffy® (epinephrine nasal spray) at 2025 American Academy of Allergy, Asth...
February 18, 2025
ARS Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Conference
February 5, 2025
ARS Pharmaceuticals Launches neffyinSchools Program Providing Free Life-Saving Needle-Free Epinephrine For Emergency Use to Eligible K-12...
January 21, 2025
ARS Pharmaceuticals Announces Preliminary Fourth Quarter 2024 Financial Results and 2025 Objectives for neffy® (epinephrine nasal spray)
January 13, 2025
ARS Pharmaceuticals Files for Approval of neffy® in Canada and the United Kingdom on Behalf of Licensing Partner ALK-Abelló A/S
January 6, 2025
ARS Pharmaceuticals Announces neffy® (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies
December 19, 2024